The value of EGFR in individualized treatment for brain metastases in non-small cell lung cancer

Abstract

The prognosis of brain metastases in non-small cell lung cancer (NSCLC) is poor, and patients with EGFR mutations are more likely to have brain metastases. The epidermal growth factor receptor (EGFR) gene status has changed the direction of treatment for NSCLC patients with brain metastases. The development of EGFR tyrosine kinase inhibitors (EGFR-TKI) has prolonged the survival time of NSCLC patients with brain metastases. The treatment of patients with NSCLC brain metastases should be individualized according to the clinical symptoms, tumor stage, and different gene mutation status. As cancer is heterogeneous at the molecular level, related biomarker studies looking for individualized characteristics are recommended.